Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial

Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete r...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 387; no. 10014; pp. 136 - 145
Main Authors:	Weisz, Giora, Généreux, Philippe, Iñiguez, Andres, Zurakowski, Aleksander, Shechter, Michael, Alexander, Karen P, Dressler, Ovidiu, Osmukhina, Anna, James, Stefan, Ohman, E Magnus, Ben-Yehuda, Ori, Farzaneh-Far, Ramin, Stone, Gregg W
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 09.01.2016 Elsevier Limited
Subjects:	Aged Angina pectoris Angina Pectoris - therapy Angioplasty Cardiology Coronary Artery Disease - therapy Coronary Stenosis - therapy Double-Blind Method Drug therapy Female Heart attacks Hospitalization - statistics & numerical data Humans Internal Medicine Intervention Ischemic Attack, Transient - epidemiology Male Medical prognosis Myocardial Infarction - epidemiology Myocardial Ischemia - epidemiology Myocardial Ischemia - therapy Myocardial Revascularization - statistics & numerical data Percutaneous Coronary Intervention Ranolazine - therapeutic use Sodium Channel Blockers - therapeutic use Stroke - epidemiology INW, Russia USA Israel ANE, Europe
ISSN:	0140-6736, 1474-547X, 1474-547X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!